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Atypical Ocular Manifestations
From the 32 patients with atypical ocular symptoms, there was no report of co-infections with other agents causing ocular manifestations such as Onchocerca volvulus and/or Chlamydia trachomatis, nor were onchocerciasis or trachoma mentioned as possible causes of the manifestations observed. Supplementary Table 1 summarizes the information on ocular manifestations; the references are those in Section 1: Literature Review (Supplementary References).
Eosinophilia and Co-Infections
There were 199 cases with eosinophilia (defined as a peripheral eosinophil blood count >0.5 x 10 9 cells or a peripheral blood eosinophil count ≥6% [1] . Of these, 182 (91.5%) did not have co-infecting helminths reported, but malaria was recorded at the time of consultation in 5, amoebiasis in 4 (one of whom also had Trichuris trichiura, one had hookworm, and one had Strongyloides stercoralis), trypanosomiasis in 1 (who also had schistosomiasis) and tuberculosis in 1. Most infectious causes of peripheral blood eosinophilia are parasitic, and particularly helminth infection; protozoa, in general, do not cause eosinophilia [2] . There were 17 (8.5%) cases with co-infecting helminths, 8 with Not reported * Loa loa microfilariae can be found in bloodless skin snips [3] .
Statistical Analyses

Chi-Squared Test
Pearson's chi-squared test was used to test whether there was a statistically significant association between blood microfilarial density (MFD) levels and atypical presentation; where MFD levels had been categorised as: Zero (amicrofilaraemic, no mf detectable in blood smear), Low (greater than 0 but < 8,000 mf/ml) and High (≥ 8,000 mf/ml). All individuals for whom information on manifestation (either typical or atypical) and MFD were included. There are, therefore, more individuals included in this test than in the subsequent regression-based analyses, where data on a wider range of factors, specifically an individual's age, sex, residency status and MFD level (and eosinophilia status for Model 2) were required for them to be included. Pearson's chi-squared test using these data gave a chi-squared value of 13.492, which, with 2 degrees of freedom, yielded a p-value of 0.001176. We defined two multivariate logistic regression models (Model 1 and Model 2, the results of which are detailed in Figure 3 of the main text) that were fitted to the IPD collated through the systematic literature review. For both models, age was included as a continuous variable. Sex was defined as a categorical variable, with a reference of 0 for women and 1 for men. Residency status was included as a categorical variable; in almost all instances, residency status could easily be determined from the article text, but in a small number of cases (n = 3 individuals), it was impossible to ascertain whether an individual was living abroad or in an endemic country at the time of the consultation detailed in the reference, and thus that individual was excluded from the analyses presented here. MFD levels were included as a categorical variable, with an individual's MFD being either "Zero", "Low" or "High" (as defined in the section above). Eosinophilia status was also included as a categorical variable, with a reference value of 0 if the individual was not eosinophilic, and a value of 1 if the patient presented with eosinophilia (with being eosinophilic defined as having a peripheral eosinophil blood count > 0.5 x 10 9 cells or a peripheral blood eosinophil count ≥ 6% as described in the main text). The number of individuals in each category for the categorical variables is detailed in Supplementary Table 3 . In addition to Models 1 and 2, we also explored a second set of models, defined here as Models 3 and 4. Although Models 3 and 4 share the same structure as Models 1 and 2, they differ in their categorisation of MFD levels. Instead of three categories (Zero, Low and High), individuals were assigned to one of four categories based on the MFD recorded. These categories were: Zero (amicrofilaraemic, no mf detectable in blood smear), Low (> 0 but < 8,000 mf/ml), High (≥ 8,000 but < 30,000 mf/ml) or Very High (≥ 30,000 mf/ml). The categorisations were chosen based upon their relationship with the risk of marked or severe adverse events (SAEs) following ivermectin treatment, with ≥ 8,000 mf/ml and ≥ 30,000 mf/ml associated, respectively, with an increased risk of marked adverse events (reversible functional impairment for several days), and permanent neurological sequelae including fatal encephalopathy [4] .
Supplementary
Multivariate Logistic Regression
Supplementary
Analysis of these models revealed similar results to those of the models presented in the main text, although the additional granularity granted through subdivision of the MFD categories allowed resolution of a potential dose-response relationship between MFD levels and the odds of presenting atypically. Specifically, for Model 3, individuals with high MFD levels had a significantly increased risk of atypical manifestations (OR 8.27, 95% CI 1.27-53.71, p = 0.03), and individuals with very high MFD levels had an even greater risk (OR 10.84, 95% CI 1.04-113.07, p = 0.05) ( Supplementary Table 4, Model 3 ). Neither zero nor low MFD levels were associated with an increased risk of atypical manifestations.
Similar results were observed for Model 4 (including eosinophilia status), although the significance associated with high MFD level was lost (Supplementary Table 4 , Model 4), a feature likely attributable to the substantial drop in sample size that accompanied further conditioning an individual's inclusion if their eosinophilia status was reported. However, individuals with very high MFD level were still at a (marginally) significantly higher risk of atypical manifestations (OR 12.72, 95% CI 0.97-167.25, p = 0.05). The stratification of MFD into a larger number of levels led to significant reductions in the average size of each group, particularly for the high and very high categories ( Supplementary Table 4 ), leading to substantial uncertainty in these estimates. Nevertheless, these results support the possibility of a dose-response relationship between atypical presentation and the intensity of microfilarial infection an individual harbours. The number of individuals in each category for the categorical variables considered in the analyses is provided in Supplementary Table 4 and the results of the models in Supplementary Table 5 .
Supplementary Table 5: Results from Multivariate Logistic Regression Models 3 and 4.
Individuals are categorised into one of four categories based on their MFD levels; either Zero (amicrofilaraemic, no mf detected in blood smear), Low (> 0 but < 8,000 mf/ml blood), High (≥ 8,000 but < 30,000 mf/ml blood) or Very High (≥ 30,000 mf/ml blood). 
Confidence Interval Calculation: Non-Parametric Bootstrap
In order to calculate the 95% confidence intervals (CIs) for the mean MFD of each residency status group shown in Figure 4 of the main text), an ordinary non-parametric re-sampling technique [5] was used. This process involved the following steps:
1. For each residency status group of size n, resampling (at random) with replacement of n patient MFD was conducted. 2. The mean of this newly generated sample was calculated. 3. Steps 1 and 2 were repeated 10,000 times to yield an empirical sampling distribution of the mean MFD for each different residency status group.
